3386 COSMO BIO COMPANY, LIMITED - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3386

TSE Standard

COSMO BIO COMPANY, LIMITED

1,358

JPY

-40

(-2.86%)

Dec 5, 3:30 pm JST

8.78

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	9,231	1,048	1,099	737	126.9	36	Feb 14, 2022	J-GAAP
Dec, 2022	9,553	816	790	517	89.1	36	Feb 14, 2023	J-GAAP
Dec, 2023	9,340	519	653	442	76.0	30	Feb 14, 2024	J-GAAP
Dec, 2024	10,037	318	364	262	45.1	50	Feb 14, 2025	J-GAAP
Dec, 2025 Guidance	10,700	490	580	430	75.8	50	Feb 14, 2025	J-GAAP
YoY	+6.6%	+54.1%	+59.3%	+64.1%	+68.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 14, 2020	7,750	430	490	310	18	J-GAAP
	Jul 21, 2020	7,800	590	660	540	18	J-GAAP
	Dec 17, 2020	7,800	590	660	540	34	J-GAAP
Results	Feb 12, 2021	8,092	752	817	674	34	J-GAAP
Dec, 2021	Feb 12, 2021	Available in future release
	Jul 27, 2021
	Dec 16, 2021
Results	Feb 14, 2022
Dec, 2022	Feb 14, 2022
	Jul 25, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024
	Aug 5, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025	10,700	490	580	430	50	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2000 Changed	2,985	－	Available in future release
Dec, 2001	4,181	+40.1
Dec, 2002	4,527	+8.3
Dec, 2003	4,810	+6.3
Dec, 2004	4,970	+3.3
Dec, 2005	5,498	+10.6
Dec, 2006	5,936	+8.0
Dec, 2007	5,906	-0.5
Dec, 2008	5,622	-4.8
Dec, 2009	5,282	-6.0
Dec, 2010	6,676	+26.4
Dec, 2011	7,192	+7.7
Dec, 2012	7,241	+0.7
Dec, 2013	7,050	-2.6
Dec, 2014	7,235	+2.6
Dec, 2015	7,357	+1.7
Dec, 2016	7,427	+1.0
Dec, 2017	7,068	-4.8
Dec, 2018	7,261	+2.7
Dec, 2019	7,590	+4.5
Dec, 2020	8,092	+6.6
Dec, 2021	9,231	+14.1
Dec, 2022	9,553	+3.5
Dec, 2023	9,340	-2.2
Dec, 2024	10,037	+7.5
Dec, 2025 Guidance	10,700	+6.6	490	+54.1	580	+59.3	75.8	+68.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	9,340	519	5.56	5.36	4.17	0.88	76.0
Dec, 2024	10,037	318	3.17	3.01	2.32	0.89	45.1
Dec, 2025 Guidance	10,700	490	4.58	4.63	3.51	0.87	75.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	10,037	1,048	1,099	737	126.9
Fiscal Year	Dec, 2024	Dec, 2021	Dec, 2021	Dec, 2021	Dec, 2021

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	4,442	190	170	110	19.0	20	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	4,513	61	101	81	13.9	16	Feb 14, 2024	J-GAAP
Jul - Dec, 2024	4,908	-4	27	4	0.7	36	Feb 14, 2025	J-GAAP
Jul - Dec, 2025 Guidance	5,298	214	237	180	31.7	25	Aug 5, 2025	J-GAAP
YoY	+7.9%	－	+777.8%	+4,400.0%	+4,497.1%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	816	-7	284	-291	-236	3,036	29.44	J-GAAP
Dec, 2023	519	-22	736	-758	-201	2,826	25.99	J-GAAP
Dec, 2024	318	24	241	-217	-479	2,393	20.41	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	6,877	447	554	366	62.8	84.8	Nov 7, 2023	J-GAAP
Jan - Sep, 2024	7,409	369	384	291	49.9	105.5	Nov 7, 2024	J-GAAP
Jan - Sep, 2025	7,885	275	369	272	48.0	63.6	Nov 7, 2025	J-GAAP
YoY	+6.4%	-25.5%	-3.9%	-6.5%	-3.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	2,463	72	99	76	13.1	2.9	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	2,943	305	299	230	39.6	10.4	May 9, 2024	J-GAAP
Apr - Jun, 2024	2,186	17	38	28	4.8	0.8	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	2,280	47	47	33	5.7	2.1	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	2,628	-51	-20	-29	-5.0	-1.9	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	3,093	273	293	212	37.2	8.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	2,309	3	50	38	6.7	0.1	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	2,483	-1	26	22	3.9	0.0	Nov 7, 2025	J-GAAP
YoY	+8.9%	－	-44.7%	-33.3%	-31.4%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	2,266	+13.6	Available in future release
Jan - Mar, 2021	2,878	+18.9
Apr - Jun, 2021	1,957	+28.2
Jul - Sep, 2021	2,046	+8.8
Oct - Dec, 2021	2,350	+3.7
Jan - Mar, 2022	3,047	+5.9
Apr - Jun, 2022	2,064	+5.5
Jul - Sep, 2022	2,016	-1.5
Oct - Dec, 2022	2,426	+3.2
Jan - Mar, 2023	2,828	-7.2
Apr - Jun, 2023	1,999	-3.1
Jul - Sep, 2023	2,050	+1.7
Oct - Dec, 2023	2,463	+1.5
Jan - Mar, 2024	2,943	+4.1
Apr - Jun, 2024	2,186	+9.4
Jul - Sep, 2024	2,280	+11.2
Oct - Dec, 2024	2,628	+6.7
Jan - Mar, 2025	3,093	+5.1
Apr - Jun, 2025	2,309	+5.6
Jul - Sep, 2025	2,483	+8.9	-1	－	26	-44.7	3.9	-31.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,093	578	565	366	63.2
Fiscal Year	Mar, 2025	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Announce	Accounting Standards
Dec, 2022	1,385.20	78.1	10,313	8,052	5,560	Feb 14, 2023	J-GAAP
Dec, 2023	1,447.08	77.7	10,872	8,444	5,805	Feb 14, 2024	J-GAAP
Dec, 2024	1,565.00	76.5	11,723	8,967	5,891	Feb 14, 2025	J-GAAP
Jan - Sep, 2025	ー	75.6	12,266	9,279	5,816	Nov 7, 2025	J-GAAP

COSMO BIO COMPANY, LIMITED(3386) Financial Results